Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1136/pn-2023-004033 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Usefulness and safety of remimazolam in upper gastrointestinal endoscopy: A comparative study between elderly and non-elderly patients.
DEN Open
April 2025
Department of Anesthesiology, Fujimoto General Hospital Miyazaki Japan.
Objectives: In gastroenterology, sedation demand is increasing, although elderly patients are more prone to experiencing adverse events. Remimazolam, a novel ultra-short-acting benzodiazepine, may reduce recovery time after endoscopic procedures.
Methods: This study was a secondary analysis of the investigator-initiated trial, which investigated the efficacy and safety of remimazolam in gastrointestinal endoscopy (REM-IICT JP01).
Optimizing Propranolol Therapy for Infantile Hemangiomas: The Role of the Multidisciplinary Team.
Cureus
December 2024
Department of Pediatrics, Toranomon Hospital, Tokyo, JPN.
Background: Oral propranolol therapy is currently the first choice for infants with infantile hemangiomas (IHs) requiring systemic treatment. This study aims to evaluate the safety and effectiveness of oral propranolol therapy for IHs and to assess the role of a multidisciplinary medical team in supporting optimal treatment.
Materials And Methods: Clinical data were retrospectively reviewed from medical records in 150 Japanese infants with IH treated with propranolol orally at Toranomon Hospital.
A Saudi Heart Association Position Statement on Cardiovascular Diseases and Diabetes Mellitus.
J Saudi Heart Assoc
December 2024
Bugshan Center, Jeddah, Saudi Arabia.
Background: Cardiovascular disease (CVD) and diabetes mellitus are prominent public health concerns in Saudi Arabia owing to their increasingly high prevalence and burden. Based on this, the Saudi Heart Association (SHA) set out to develop an official position statement on CVD and diabetes mellitus, with a focus on the prevention and management of these conditions and relevant special populations in the context of Saudi Arabia.
Methods: A multidisciplinary panel of experts met under the auspices of the SHA in a series of meetings to review and discuss available evidence on the prevention and management of comorbid CVD and diabetes mellitus.
Plasma biomarkers of amyloid, tau, astrogliosis, and axonal injury in a mixed memory clinic cohort.
Alzheimers Dement (Amst)
January 2025
Introduction: Studies have shown that blood biomarkers can differentiate dementia disorders. However, the diagnosis of dementia still relies primarily on cerebrospinal fluid and imaging modalities. The new disease-modifying treatments call for more widely applicable biomarkers.
View Article and Find Full Text PDFTreatment of Venous Thromboembolism with Edoxaban over 18 Months: Results from ETNA-VTE Europe.
Thromb Haemost
January 2025
Guy's and St Thomas' NHS Foundation Trust, King's College London, United Kingdom.
Background: The benefits and risks of extending anticoagulant treatment beyond the first 3 to 6 months in patients with venous thromboembolism (VTE) in clinical practice are not well understood.
Methods: ETNA-VTE Europe is a prospective, noninterventional, post-authorization study in unselected patients with VTE treated with edoxaban in eight European countries for up to 18 months. Recurrent VTE, major bleeding, and all-cause death were the primary study outcomes.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!